HHS to Establish Presumptive Injury Table for COVID-19 Vaccines, Expanding CICP Access Under RFK Jr.

The proposed table targets the Countermeasures Injury Compensation Program, which has processed over 12,000 COVID-19 vaccine claims since 2020 with fewer than 1 percent compensated to date. Unlike the Vaccine Injury Compensation Program's established table for childhood vaccines, CICP lacks presumptions, requiring petitioners to demonstrate specific causation through medical records and expert testimony. This shift follows RFK Jr.'s public statements on inadequate safety data and aims to address documented delays averaging 18 months per claim. The change would cover conditions with emerging epidemiological signals such as myocarditis in young males, where VAERS and VSD data show rates of 1 in 2,700 to 1 in 6,000 doses in certain age groups.

Existing observational data from large cohorts in NEJM and JAMA link mRNA vaccines to rare myocarditis and pericarditis cases, predominantly within seven days of dosing, with most resolving but some requiring hospitalization. The new table could incorporate these signals alongside thrombosis with thrombocytopenia syndrome from viral-vector products, drawing on EMA and FDA pharmacovigilance reviews. Critics note that expanding presumptions risks overcompensation for coincidental events, while supporters argue current denial rates undermine program credibility. Funding implications include potential drawdown of the $3.5 billion appropriation, affecting future claims processing capacity.

This policy diverges from prior administrations' reliance on case-by-case adjudication, mirroring elements of the 1986 National Childhood Vaccine Injury Act but applied to emergency countermeasures. It intersects with ongoing debates over program structure, including calls to transfer COVID claims to VICP for stronger due-process protections. International comparisons, such as UK's Vaccine Damage Payment Scheme, show similar tensions between accessibility and fiscal sustainability when tables are updated.

Next steps involve a notice of proposed rulemaking with 60-day public comment, followed by expert panel review of adverse event data from V-safe and BEST Initiative systems. Finalization could occur within nine months, contingent on litigation from manufacturers citing PREP Act liability shields.